Back to search
FDAFDA · Food and drugs·Recall number D-0098-2023

Rifampin Capsules, 300 mg, 30 count blister card, Rx only, Mfg: Lupin Pharma, Baltimore, MD 21202, original NDC 68180-0659-07, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, Repackaged NDC 70518-2404-00.

Published January 18, 2023 · Recall initiated: December 20, 2022

Summary

FDA records drug Class II recall D-0098-2023, published January 18, 2023 and initiated December 20, 2022. Recalling firm: RemedyRepack Inc.; Status: Terminated; Reported quantity: 132 Cards of 30 = 3960 Tablets; Lot: Lot #: J0599794-022322, exp. date 02/28/2023; J0621369-052622, exp. date 06/30/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRepack Inc.
Distributor
Product was distributed to one account in PA.
Lot
Lot #: J0599794-022322, exp. date 02/28/2023; J0621369-052622, exp. date 06/30/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rifampin Capsules, 300 mg, 30 count blister card, Rx only, Mfg: Lupin Pharma, Baltimore, MD 21202, original NDC 68180-0659-07, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, Repackaged NDC 70518-2404-00. recalled?

Yes. FDA published recall D-0098-2023 on January 18, 2023. Reported hazard: Failed Impurities/Degradation specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter